GLPwatch

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227 · Active, not recruiting

Last updated 2026-05-28

This study is testing whether the medication semaglutide helps children and teenagers with obesity lose weight.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 210 people Planned (estimated).
Who can join Ages 6–18 · all sexes
Timeline Started 2023-07 · est. completion 2026-12
Where 56 sites · Austria, Belgium, Denmark, Germany, Israel, Mexico, Portugal, Sweden, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT05726227 ↗

Description as written by the study sponsor.

This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults. The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).

Treatments tested

Main thing measuredGroup Kids: Change in body mass index (BMI)
SponsorNovo Nordisk A/S
Conditions studiedObesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05726227 ↗